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ABSTRACT
In this study, a novel anticancer reagent based on polyplexes nanoparticles 
was developed. These nanoparticles are obtained by mixing negatively charged 
polyelectrolytes with the antitumour cationically-charged pseudopeptide N6L. 
Using two in vivo experimental tumor pancreatic models based upon PANC-1 and 
mPDAC cells, we found that the antitumour activity of N6L is significantly raised 
via its incorporation in polyplexed nanoparticles. Study of the mechanism of action 
using affinity isolation and si-RNA experiments indicated that N6L-polyplexes are 
internalized through their interaction with nucleolin. In addition, using a very 
aggressive model of pancreatic cancer in which gemcitabine, a standard of care for 
this type of cancer, has a weak effect on tumour growth, we observed that N6L-
polyplexes administration has a stronger efficacy than gemcitabine. Biodistribution 
studies carried out in tumour-bearing mice indicated that N6L-polyplexes localises 
in tumour tissue, in agreement with its antitumour effect. These results support the 
idea that N6L nanoparticles could develop into a promising strategy for the treatment 
of cancer, especially hard-to-treat pancreatic cancers.
INTRODUCTION
Nanomedicine, the implementation of 
nanotechnology-based principles and materials in the 
medical area, opens new fields of multidisciplinary 
investigations that could potentially offer innovative sets 
of diagnostic and therapeutic tools adaptable to several 
diseases such as cancer. This strategy opens new avenues 
for better, more adapted or improved treatments of patients. 
In drug delivery, nanocarriers have been developed that 
are conventionally defined as engineered structures of 
nanometric sizes having the ability to carry and release 
therapeutic molecules to specific disease-related sites. 
Over the past few years, polymeric nanostructures from 
natural or synthetic polymers have been extensively 
investigated in order to develop an effective cancer drug 
delivery system, which yields a higher therapeutic index 
of the drug with lower toxicity towards normal tissues, 
with a few formulations tested under phase I/II human 
trials [1]. In cancers indeed, due to the high production of 
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proangiogenic factors, tumour vasculature is abnormal with 
leaky vessels displaying highly tortuous geometries and 
hyperpermeabilities [2, 3]. These vascular anomalies result 
in large-size pores in the tumour vasculature as compared 
to normal tissues, opening a way for nanoparticles to 
preferentially accumulate in solid tumours [4], ultimately 
yielding higher therapeutic index of the drug linked to the 
nanoparticles, and sometimes providing lower toxicities 
toward normal cells as well.
Up to now, developed nanoparticles have been 
designed to release the active drug according to two 
mechanisms, by progressive physicochemical release of 
the drug encapsulated in the nanoparticle, or as the result 
of a cleavage reaction involving a covalent bond between 
the active species and an inert polymer included in the 
particle, namely the polymer prodrug approach [5]. An 
alternate design could also be considered, if a particle can 
be built whose surface is decorated by multiple copies of 
a substructure acting as a ligand according to a multivalent 
drug approach. N6L is an anticancer drug developed by 
our group whose oligomeric structure is made of identical 
tripeptide repeat units (KΨPR) and whose activity is 
known to depend upon the number of these units [6]. In this 
context, the hexamer named N6L, currently investigated 
under phase IIa trial for cancer therapy, corresponds to 
a compromise between improved activities, mounting 
purification difficulties and higher production cost. The 
above multivalent pseudopeptides target cell surface 
nucleolin (NCL) and induces apoptosis of tumour cells [6, 
7]. N6L decreases the tumour growth of pancreatic ductal 
adenocarcinoma (PDAC) and reprograms the angiogenesis 
process by inhibiting angiopoietin-2 [8]. In addition to its 
effect on tumour growth, N6L also inhibits the migration 
and invasion of melanoma and PDAC cells [9]. Moreover, 
high affinity binding of N6L was demonstrated for sulfated 
glycosaminoglycans (GAG), as well as a displacement 
of GAG-bound tissue inhibitor of metalloproteinases-3, 
emphasizing that N6L binds to sulfated GAG [10].
In the present study, we aimed at testing whether 
higher multivalencies of N6L can be obtained via a 
simple polyplex-based synthesis of nanoparticles acting 
as scaffolds to display even larger number of active 
ligands at their surface. An alternative approach to drug-
delivery nanoparticles is proposed that explores whether 
the nanoparticle itself can be used as the active ingredient 
rather than as a carrier whose sole mission is to transport 
the active ingredient and to release it over time.
RESULTS
Synthesis of N6L Polyplexes
It is well known that mixing opposite charged 
polyelectrolytes results in the formation of small particles 
of nano- to micrometric sizes [11]. These particles, usually 
referred to as polyplexes, are colloidally stable, and in 
most cases, do not aggregate due to repulsive force. In 
biomedicine, these polyplexes have mostly been used 
as carriers to deliver therapeutic nucleic acids [12]. In 
a previous study, we reported that N6L, which under 
physiological pH is a highly-charged oligomer with 24 
positive charges distributed over a small volume, shows a 
high affinity interaction for heparin [6]. In this study, we 
sought to test whether the interaction of N6L with heparin 
or other sulfated glycoaminoglycans could lead to the 
formation of nanostruture such as polyplexes.
To test whether N6L could yield polyplexes with 
heparin, an aqueous solution containing both N6L and 
heparin was prepared and added to a dynamic light 
scattering (DLS) cuvette after mixing to reveal the presence 
of nanoparticles. Results indicated that a monodisperse size 
distribution is observed, with an average particle diameter 
of 194 ± 3 nm at final concentrations of 14.7 μM and 100 
μg/mL in N6L and heparin, respectively (Supplementary 
Figure 2). An additional measurement after 24 h at room 
temperature led to an equally monodisperse nanoparticle, 
with a diameter of 193 ± 10 nm (not shown).
To validate these data, similar experiments were 
performed using another sulfated glycosaminoglycan, 
chondroitin sulphate C (CS-C), as the polyanionic 
macromolecule, at 10 or 1000 μg/mL and 73 μM for CS-C 
and N6L, respectively. A monodisperse hydrodynamic 
size distribution was observed with an average diameter 
of 279 ± 11 nm, at concentrations of 10 μg/mL and 73 
μM in CS-C and N6L, respectively (Figure 1A). When 
higher concentrations of CS-C (1000 μg/mL) were used, 
relatively large and polymodal size distributions were 
observed, with average diameters at 228 ± 25 and 973 
± 187 nm for the two major populations (Figure 1B). 
Confirming the data presented in Figure 1A, we observed 
by transmission electronic microscopy (TEM) that 
nanoparticles obtained by mixing a solution of 10 μg/ml 
CS-C and 73 μM N6L have a particles diameter of about 
100 nm (Figure 1C). We next studied the stability of these 
N6L-polyplexes over 24 hours periods by measuring 
the change in particle hydrodynamic size. As shown in 
Table 1, while N6L-polyplexes obtained with 1000 μg/
mL CS-C remained relatively stable over a period of 4 
hours, a significant size increase of N6L-polyplexes 
obtained with 10 μg/mL CS-C could be observed 8 hours 
after the polyplex formation, reaching a diameter of 381 ± 
88 nm. Determination of the zeta potential indicated that 
polyplexed N6L obtained from 73 μM N6L mixed with 
10 and 1000 μg/mL of CS-C display values of +34.2 ± 
6.5 mV and -38.1 ± 7.3 mV, respectively, numbers that 
remained stable over at least 24 h (Figure 1D).
To examine the potential anticancer activity of 
N6L-polyplexes, we tested its effect on the viability of the 
well-established human pancreatic cancer cell line PANC-
1. Cells were treated with several concentrations of N6L 
ranging from 4.6 to 147 μM, alone or in the presence of 
several concentrations of CS-C. As shown in Figure 1E, 
as compared to the treatment of cells with N6L alone, 
N6L-polyplexes obtained at CS-C concentrations lower 
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than 1000 μg/mL (i.e., at 100 and 10 μg/mL) displayed 
a similar effect to those observed for N6L used alone 
(Figure 1E). No effects on the cell viability could be 
observed whatever the concentration of CS-C used in the 
experiment (Supplementary Figure 3).
Taken together, all these observations 
provide evidences that mixing N6L with sulfated 
glycoaminoglycans like CS-C induces the formation 
of polyplexed nanoparticles, according to a global 
aggregation mechanism schematized in Figure 1F. For the 
rest of the study, we decided to investigate the properties 
of N6L-polyplexes obtained by mixing N6L with 10 μg/
mL of CS-C.
Figure 1: N6L and anionically charged polyelectrolytes spontaneously assemble into functional polyplexed nanoparticles. 
(A and B) DLS measurement of particle size distribution measured after mixing chondroitine sulphate (CS-C) with N6L in water at 23°C 
(final concentrations for CS-C of 10 μg/mL (A) or 1000 μg/mL (B), and 73 μM for N6L in both cases). These data are representative results 
obtained from three consecutive measurements of 15 runs each; (C) typical scanning transmission electron microscope (TEM) image of 
polyplexed particles obtained after mixing 10 μg/mL CS-C with 73 μM N6L in water; (D) Zeta potential determination of N6L polyplexes: 
the charge of the polyplexes obtained with 73 μM N6L and 1000 μg/ml of CS-C (black square) or with 73 μM N6L and 10 μg/mL CS-C 
(open square) were measured as a function of the incubation time ranging from 0 to 24 hours. Data smoothing using the GraphPad software 
indicates that potentials resulting from polyplexed N6L (73 μM N6L) were stable over a period of 24 hours, with value of 34.2 ± 6.5 mV 
and -38.1 ± 7.3 mV for CS-C 1000 and 10 μg/mL, respectively; (E) PANC-1 cells were treated with concentration of N6L ranging from 
4.6 μM to 147 μM, alone or polyplexed by adding CS-C at concentrations of 1000 (black circle), 100 (black triangle) and 10 μg/mL (black 
square). After 72 hours, cell growth was quantified by AlamarBlue assay according to the recommended procedure. Histograms represent 
the percentage of cell growth relative to the values of untreated cells (indicated values are means ± SEM of 3 independent experiments 
(Student t-test, n=3)); (F) schematic illustration for the obtained polyplexed structure (red: N6L building blocks, green: CS-C octamer used 
as a model for fully developed CS-C).
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Molecular functionality of N6L-polyplexes
Previous studies have shown that N6L interacts 
with nucleolin [6]. To address whether the inhibitory 
effect of the N6L-polyplexes is linked to their interaction 
to nucleolin, we performed streptavidin pull-down assays 
using PANC-1 cell lysates incubated with biotin-labelled 
N6L-polyplexes. As shown in Figure 2A, N6L-polyplexes 
interact with nucleolin in a similar way to N6L alone, 
suggesting that nucleolin might be responsible for the anti-
tumoural effect of the N6L-polyplexes.
According to our previous study in which we 
clearly showed that the mechanism of action of N6L 
occurs through its internalization in target cells [6], we 
next investigated the cell internalization of N6L-Alexa 
fluor 488 in its polyplexed form. As shown in Figure 2B 
and 2C, 10 minutes after the addition above polyplexes, 
fluorescence could be detected inside the cells. These 
data were reinforced by observations carried out when 
invalidating nucleolin expression. Efficiency of si-
nucleolin (siNCL) is shown by Western blot analysis 
(Figure 2B). As evidenced when compared to a control 
(SiCtrl alexa N6L-polyplex), inhibition of nucleolin 
expression (siNCL alexa N6L-polyplex) prevented N6L-
polyplex internalisation (Figure 2C). Taken together, these 
data indicated that N6L-polyplex is rapidly internalized 
into the cell through nucleolin.
In vivo anti-tumoural and anti-metastatic effect 
of N6L polyplexes
In vivo anti-tumour activity of N6L polyplexes 
was then analysed using subcutaneous tumor xenograft 
of PANC-1 cells. As shown in Figure 3, treatments with 
N6L alone had no significant effect on PANC-1 xenograft 
tumour growth. In sharp contrast, N6L polyplexes 
significantly inhibited tumour growth by 85% (p<0.05) 
(Figure 3). No significant effect of CS-C alone could 
be observed. Immunohistological analysis of tumour 
indicated that treatment with N6L polyplexes significantly 
decreased Ki67 positive cells by 53 % (p<0.001) 
(Figure 4A). Moreover, the area occupied by the tumour 
vasculature decreased by 70 % (p<0.001) (Figure 4B).
All animals were closely monitored during the 
treatment and no toxicity could be evidenced in the 
various groups involved in the experiments, including the 
group treated with the N6L polyplexes (data not shown).
We then evaluated the antitumour effect of N6L 
polyplexes in the mPDAC orthotopic model in which N6L 
inhibited tumor growth [8]. After 3 weeks of treatment, 
N6L decreased the tumour volume by 42 % (p < 0.001), 
a value close to the literature value obtained when 
using gemcitabine (45 % (p < 0.01)) [8]. Interestingly, 
N6L polyplexes displayed a greater antitumour activity 
compared to gemcitabine by significantly reducing tumour 
burden by 72 % (Figure 5). A treatment with CS used as a 
single agent did not exert significant inhibitory effect on 
PDAC tumours (not shown).
Collectively, these results demonstrated that N6L 
polyplexes have a much stronger antitumoural effect than 
N6L used alone.
Biodistribution of N6L and N6L-polyplex
We sought to correlate the effects of N6L 
polyplexes with the ability to be delivered to the tumour 
in the mPDAC model. In order to reach this objective, we 
performed comparative tissues distribution studies using 
injections of fluorescent N6L polyplexes and fluorescent 
N6L alone. Pancreas cancer tissues from mPDAC mice 
Table 1: Evolution of polyplex sizes as a function of time
Polyplex CS/N6L (mg/μM) Time (h) Size 1 (nm) Size 2 (nm)
1000/73 0* 187 ± 15 1190 ± 420
 1 245 ± 85 1150 ± 245
 4 228 ± 25 973 ± 187
 8 nv nv
 24 nv nv
10/73 0* nv nv
 1 nd -
 4 279 ± 11 -
 8 460 ± 24 56 ± 37
 24 616 ± 88 97 ± 1
The sizes of the particles were determined by DLS as described in Materials and Methods. nv: not validated; nd: not 
determined. (*) Size determination was measured 15 minutes after having mixed N6L and CS-C.
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Figure 2: Biological properties of N6L-polyplexes. (A) Polyplexed N6L interacts with nucleolin. PANC-1 cells were incubated 
(lane N6L and N6L-polyplex) with 5 μM of biotin-labeled N6L in soluble (lane N6L) or polyplexed form (N6L-polyplex) or CS-C as a 
control (lane CS-C) for 1 h. N6L-interacting proteins were isolated by incubating cell lysates with avidin-agarose beads. Samples were 
analysed by SDS-PAGE, and Western blotting performed by using an anti-nucleolin antibody. (B and C) PANC-1 cells pre-treated (or 
not) with nucleolin siRNA (siNCL N6L-polyplex), GFP siRNA (siCtl – N6L-polyplex), as described in Materials and Methods, were 
incubated for 10 min with 2 μM of polyplexed N6L-Alexa fluor 588. Cells were then fixed in paraformaldehyde, stained with diamidino-
2-phenylindole (DAPI) (Molecular Probes), and analysed. The efficiency of si-nucleolin is shown in the figure by immunohistology using 
anti-nucleolin antibody and (B) by Western blot analysis.
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were examined 6 and 12 hours after intravenous injection 
of either polyplexed N6L-alexa 488 or N6L-alexa 488 
used alone. A strong fluorescent signal was observed 
in sections of pancreatic cancer tissues of mice injected 
with the polyplexed N6L-alexa 488 (Figure 6A and 6B). 
Fluorescence could be observed starting from 6 hours 
after the injection of N6L polyplexes (Figure 6A) to 
12 hours (Figure 6B). The fluorescent signal was much 
higher in tumours treated by N6L polyplexes than N6L 
alone (Figure 6D and 6E). Whatever the molecular form 
of N6L-alexa fluor 488 injected, it is noteworthy that no 
fluorescence could be observed in sections of normal 
pancreatic tissue (Figure 6C and 6F).
DISCUSSION
Polyplexed nanoparticles have been already used in 
cancer therapies, not only in research but also increasingly 
in clinical trials. However, most of these studies are based 
on the use of polyplexes made from DNA and polycations 
of different natures in the perspectives of non-viral 
delivery systems for cancer gene therapy. Due mainly to 
their instability, few studies have been reported on the 
therapeutical use of polyplexes other than the DNA-based 
ones. In this study, a stable polyplex nanoparticles with 
antitumour activities were obtained through self-assembly 
Figure 3: N6L polyplexes inhibit tumour growth of N6L-resistant tumours. Athymic mice were subcateneously injected with 
PANC-1 cells. Ten days after cell injection, mice were treated with intraperitoneal injections of either N6L (2 mg/kg of body weight) or 
N6L polyplexes (2 mg/kg, ratio CS-C/N6L of 1/8 w/w), CS-C (0.26 mg/kg of body weight), or PBS as control, three times per week. The 
tumour volume was measured as described in Materials and Methods. Bars ± SEM (n = 9 per group).
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Figure 4: Effect of N6L-polyplexes on tumour proliferation and vascularisation. Frozen tumour sections were fixed, saturated 
with BSA 3% for 1 h at room temperature, and incubated with anti-ki67 (A) or anti-MECA32 (B). After washing, sections were incubated 
with anti IgG Alexa Fluor-555. Nuclei were stained with DAPI, and immunofluorescence images were captured by confocal microscopy. 
Acquisitions were carried out on multiple tissue sections (5 field per mouse, n = 5), and quantification analysis was performed by the 
ImageJ sofware.
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between N6L and sulfated glycosaminoglycans used as 
anionic polymers.
From a physic-chemical perspective, polyplexes are 
particles of small sizes suspended in water that form as the 
result of strong attractive electrostatic interactions between 
charged polymers of opposite charges in aqueous solutions 
[13]. Their sizes, typically in the nanometric range, 
depends very much on both the nature of the involved 
polyelectrolytes and the mixing conditions (e.g., the molar 
ratio between the partners, their initial concentrations, the 
presence of other species or the temperature) [14, 15]. 
As indicated above, DNA/RNA-based polyplexes with 
various positively charged polyelectrolytes have been 
particularly investigated in the past few decades as a 
potential non-viral delivery method for gene therapy [16]. 
As heparin is characterized by a highly negatively charged 
polysaccharide backbone comprised of sulfated uronic 
acid-(1→4)-D-glucosamine repeat units, and N6L displays 
24 positive charges at physiological pH, it is tempting 
to assume polyplexes would be formed when mixing 
cationically-charged heparin and negatively-charged N6L 
together.
Investigated polyplexes were formed according to 
two sets of preparation conditions (i.e., in water and in a 
cell culture medium) that had been selected to mimic those 
used in the in vitro experiments. Unfortunately, it was 
impossible to obtain dependable results in a cell culture 
medium. The high concentration of proteins in such media 
Figure 5: N6L polyplexes reduce PDAC tumour growth. Immuno-competent syngenic FVB/n mices were injected with PDAC 
cells into the pancreas. One week later, either N6L alone (10 mg/kg) or N6L polyplexes (10 mg/kg) were injected (i.p.) three times a week. 
Control were carried out by injection of gemcitabine (100 mg/kg) two times a week. After three weeks of treatment, mice were sacrificed, 
and tumour volumes were measured (n = 10, student t-test, *** P < 0.001; * P < 0.05).
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Figure 6: N6L polyplexes target tumour tissue. (A) N6L-polyplex targets pancreatic tumour tissues more efficiently than N6L alone. 
Mice with established PDAC tumours (A, B, D and E) or mice without tumours (C and F) were injected with Alexa-488-stained N6L, alone 
or in a polyplexed form, and sacrificed after 6 hours (A and D) or 12 hours (B, C, E and F). Tumours were recovered, and confocal analysis 
was performed on tissue sections. Images are representative of 5 fields observed. N6L fluorescence intensity was quantified and plotted (n 
= 5 at least; student t-test, treated vs. not-treated, *** P < 0.001, ** P < 0.01). Alexa-488 N6L was not detected in normal pancreas (C and F).
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generates indeed a large scattering signal, the high number 
of small-size light-scatterers compensating for their much 
lower scattering power with respect to the one generated 
by much larger polyplex particles. This background 
scattering induces a major difficulty when attempts are 
made to mathematically generate a unique, statistically 
robust solution from the autocorrelation function from a 
single-angle scattering measurement [17, 18].
From these experiments, the conclusion could be 
reached that CS-C undeniably induces the easy formation 
of polyplexes when mixed with N6L, whatever the 
preparation conditions. In addition, the above experiments 
supported the assumption that the bulk of the bioactive 
N6L ingredient used in the upcoming in vivo and in 
vitro experiments should be located in the aggregated 
polyplexed particles, at least initially.
A remarkable feature of the results presented in 
this study is that a polyplexed structure of N6L improved 
drastically the antitumour response of N6L compared 
to N6L used alone. This effect was demonstrated using 
several tumour growth models of human pancreatic 
tumours, using heterotopic and orthotopic grafting 
experiments. Pancreatic cancer had been selected because 
they are very difficult to cure and, despite the intensive 
research efforts that have been developed so far, remains 
resistant to the majority of cytotoxic drug currently used as 
well as to conventional radiochemotherapeutical treatment 
[19]. It is noteworthy that, in the above models, the 
therapeutic effect of polyplexed N6L is better that those 
obtained with a sub-toxic dose of gemcitabine, which is 
the current reference treatment for this type of cancer. In 
addition and as previously described with N6L used alone, 
no toxicity of the polyplexed N6L could be observed 
when used at therapeutic doses. As previously described 
for N6L, the antitumour activity of N6L-polyplex is not 
specific for pancreatic cancer because antitumour effect 
of N6L-polyplex is also observed using U87 cells as target 
cells [20].
It is now well-established that, under certain 
pathophysiological circumstances like tumour 
development, tumour blood vessels become more 
permeable than under normal physiological conditions 
[21], resulting in their barriers becoming leaky. Under 
such conditions, large molecules and particles until 500 
nm in size can leave the vessel and accumulate inside the 
intersticial tissue of the tumour [22]. Among the various 
parameters modulating this effect, the most important 
appears to have biocompatible molecules displaying 
molecular weights larger than 40 kDa. In the light of 
our accumulated data, the enhancement in antitumour 
efficacy for N6L in a polyplexed form compared to N6L 
used alone could be rationalized according to the so-called 
EPR (Enhanced Permeability and Retention) effect, which 
a model is presented in Figure 7. Hence, whatever the 
N6L formulation injected to the mice, no N6L retention 
could be observed in normal pancreas tissues (Figure 7A), 
where lymphatic clearance and the absence of nucleolin 
expression at endothelial cell surfaces in normal vessels 
simultaneously occurred. Interestingly, as decribed 
for mice bearing MDA-MB 231 tumours [6] in in vivo 
imaging experiments, administration of N6L to animal 
bearing pancreatic tumours induced N6L localization 
Figure 7: Illustration of a possible mechanism for tumour bioavailability based on N6L-polyplexes. In the light of our 
accumulated data, the enhancement in antitumour efficacy for N6L in a polyplexed form compared to N6L used alone could be explained 
by EPR effect. In normal pancreas (A) in which lymphatic clearance occurs, and nucleolin expression at the cell surface of endothelial cells 
from normal vessel does not whatever the N6L formulation injected, no retention of N6L in the tissue could be observed (see Figure 6C and 
6F). (B) In contrast, administration of N6L alone (grey circles) to animals bearing pancreatic tumour localizes into tumour tissues (Figure 
6E and 7B) in which high expression of nucleolin had been observed [8]. (C) When N6L-polyplexes were administered (green and grey 
circles), it can be assumed that N6L nanoparticles are concentrated by the EPR effect to the tumour microenvironment, increasing N6L 
bioavailabilty for the tumour as shown in Figure 6A and 6B.
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in the tumour tissue (Figure 7B) where high mucleolin 
expression has been observed [8]. In the case of N6L-
polyplex administration, it can be assumed that N6L 
nanoparticles are concentrated in the tumour according to 
the EPR effect, increasing its bioavailabilty (Figure 7C) as 
compared to an administration of N6L alone. Under these 
conditions, we can assume that N6L diffuses from the 
nanoparticles to the tumour environment. This possibility 
is consistent with the observation that polyplexed N6L 
can cross a dialysis membrane with a molecular cut-
off of 8,000 Da according to the low of mass action 
(Supplementary Figure 4). Taken together, these data 
suggest that N6L polyplexes could be considered as a 
reservoir system for N6L. Surprisingly, although N6L 
binds to sulfated glycoaminoglycans with high affinity, 
N6L polyplexed with CS or heparin (not shown), retained 
its ability to inhibit the tumour cell proliferation and to 
induce apoptosis. However, it is noteworthy, that the 
biological effect of polyplexed N6L is a function of the CS 
concentration used to form the nanoparticles. As presented 
in this study, high concentration of CS inhibited the 
biological activity of N6L. This observation suggests that 
the functional domains in polyplexed N6L are constituted 
by the positive charges of KPR domains in N6L, which are 
neutralized by the negative charges in CS. This hypothesis 
is conforted by the fact that the specific activity of the 
multivalent pseudopeptide N6L is dependent upon the 
number of KPR tripeptides present as lateral branches (see 
Supplementary Figure 1) [6].
Sulfated glycoaminoglycans are natural 
polysaccharides present in mammalian tissues. They 
contribute to critical functions in the physiological 
and pathological mechanisms involved in maintaining 
homeostasis [23]. Interestingly, these polysaccharides 
have already been used as pharmacological agents in 
cancer therapies. Even if our models do not suggest any 
antitumour effect of CS alone, it cannot be excluded that 
the use of other natural or synthetic polyanionic molecules 
displaying both a high affinity for N6L and antitumour 
activities could not induce better results than those 
obtained with CS. In this context, it can be noted that 
modified CS like neoglycans induce apoptosis in myeloma 
cells, [24] and reduce or even fully prevent the growth of 
breast cancer in a xenograft model without apparent toxic 
effect. Also, highly sulfated polysaccharides isolated from 
sea cucumber display antimetastatic activity through the 
binding to P-selectin [25]. Moreover, it has been shown 
that acharan sulfate, a glycoaminoglycan isolated from 
the giant African snail, inhibits tumour growth in Lewis 
lung carcinoma without toxicity or resistance effects 
[26]. Other studies have indicated that a treatment of 
human bladder cancer cells with a combination of CS and 
either gemcitabine or mitomycin-C results in a marked 
synergic antitumoural effect [27]. These data suggest that 
it could be very interesting to use polyplexed N6L as a 
nanoparticles platform for synergistic chemotherapeutic 
drugs delivery. This possibility is currently under 
investigation using both natural and synthetic polyanionic 
molecules. Another advantage of the N6L polyplexes 
shown in this study is the ability of these nanopaticules 
to target tumour cells after their administration through 
the blood stream. This property has been already observed 
using other molecules targeting cell surface nucleolin 
such as AS1411 aptamer [28] and the F3 peptide [29], 
validating this molecular target. Recently, these molecules 
have been used to develop a nanoplatform to codeliver 
several anticancer drugs and improve the delivery of these 
molecules to cancer cells [30–33]. In previous studies, we 
have developed iron oxide nanoparticles functionalized by 
the multivalent pseudopeptide N6L that target breast tumor 
by binding to nucleolin and sulfate glycoaminoglycans. 
However, due mainly to the amount of N6L linked to 
the magnetic nanoparticles, although these nanoparticles 
target tumor, no effect on the viability of tumor cells have 
been observed [34]. From these studies, it is noteworthy 
that the combination of magnetic nanoparticles with 
sulfate glycoaminoglycans as a binding site for N6L 
will be interesting both for tumor targeting properties 
as well as antitumor activity. In addition, as previously 
mentioned [35], using N6L-polyplex approach combining 
magnetic hyperthermia and chemotherapy will represent 
an interesting therapeutic strategy for cancer treatment.
In conclusion, the development of theragnostic, 
which is a strategy that combines therapeutics with 
diagnostics constitutes a promising approach that we 
currently develop with N6L-polyplexes [34].
MATERIALS AND METHODS
Preparation of peptide constructs and N6L-
polyplexes
The synthesis of N6L was performed as previously 
described [6]. A fluorescent conjugate and biotin conjugate 
were prepared from the N6L-Cys derivative as previously 
described [6]. The conjugates were purified by high-
performance liquid chromatography and lyophilized. 
Polyplexed N6L nanoparticles aimed at biological testing 
were produced before each experiment by mixing equal 
volumes of 4 mM N6L and 20 mg/mL heparin (Sigma-
Aldrich, St Quentin Fallavien, France) or chondroitin 
sulfate C (Cs-C) (Baccinex, Courroux, Switzerland) 
solutions. After 15 minutes, an opalescent solution 
could be observed. Nanoparticles were diluted at the 
concentrations indicated in the figure captions.
Design of N6L polyplexes for structural 
characterization
Dynamic light scattering measurements were 
obtained at a 173° angle with a Nano-ZS Zetasizer from 
the Malvern company, equipped with a 4 mW He-Ne 
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laser at 633 nm. Measurements were obtained in triplicate 
(each measurement was the average of fifteen 10 seconds 
runs). The data were analyzed using Malvern Zetasizer 
Series Software v7.11. A Malvern Instruments dip cell 
was used for zeta potential measurements, each sample 
being measured in automatic mode, with an imposed 
maximum of 100 runs. For the DLS experiments, samples 
were prepared as follows. Stock solutions of N6L (2.8 
mM in water), of heparin (19.6 mg/mL in water), and 
of Cs-C under three conditions (20 mg/mL in water, 
1 mg/mL in water, and 1 mg/mL in a culture medium) 
were prepared. In the case of heparin, polyplexes were 
produced by mixing equal volumes of N6L and heparin 
solutions. After 15 minutes, the obtained mixture was 
diluted 100-fold in water. In the case of Cs-C, polyplexes 
were produced by mixing equal volumes of N6L and 
Cs-C (20 mg/mL in water solutions). After 15 minutes, 
the mixtures were diluted by a ten-fold factor, either in 
water or in the above culture medium, as indicated in the 
text or in figure captions. The obtained diluted solutions 
were further diluted by a two-fold factor, using either one 
of the following Cs-C stock solutions (i.e., 1 mg/mL in 
water or 1 mg/mL in the culture medium), as indicated in 
the text or in figure captions.
Transmission Electron Microscopy (TEM) images 
were obtained using a FEI Tecnai F20 microscope 
operating at an acceleration voltage of 200 kV. Bright 
Field images were recorded using a Gatan Orius 1000 
CCD camera. The experiments were carried out at room 
temperature. Samples were prepared as follows. A drop of 
the polyplex solution was applied on a 400 mesh copper 
grid covered by a Formvar/C membrane, which had 
previously been treated by air plasma to make the surface 
hydrophilic. After 1 minute, the excess liquid was removed 
with adsorbent paper and stained with a 0.7 % (w/w) water 
solution of uranyl acetate. The grid was subsequently dried 
in air at room temperature.
Cell culture and treatments
Human pancreatic carcinoma cell line (PANC-1; 
ATCC® CRL-1469™) was obtained from the American 
Type Culture Collection (ATCC) and cultured in DMEM 
10% FCS. For viability experiments, 1.5 x 105 PANC-
1 cells per cm2 were plated at day 0 on 48-wells cell 
culture plate (Falcon). At 24 h, cells were treated by the 
investigated molecules in DMEM 5% FCS. Quantification 
of cells was performed using the blue Alamar assay 
(Sigma-Aldrich, St Quentin Fallavien, France). Small 
interfering RNA transfection was performed using 
RNAiMAX kit (InVitrogen) and 20 nM of nucleolin 
siRNA (sequence: CCACAAGGAAAGAAGACGAAG, 
Abnova corporation, France) or GFP siRNA, which 
was used as nontargeting control siRNA (Ambion, 
Thermofisher Scientific). Efficiency of si-nucleolin 
was controled by Western blot analysis and by 
immunohistology as previously described [8]. Mouse 
pancreatic ductal adenocarcinoma (mPDAC) were 
kindly provided by Douglas Hanahan’s group (ISREC of 
Lausanne, Switzerland) [36], and cultivated as previously 
described [8].
N6L-fluorescent conjugate uptake and 
immunofluorescence
PANC-1 cells were plated at 80% of confluence on 
slides in 24 wells, and treated with 2 μM of N6L-alexa 
fluor 588 alone or in a polyplexed form for 10 minutes 
at 37°C. Cells were fixed in paraformaldehyde 4% for 
10 minutes at room temperature, and cell nuclei were 
stained with diamidino-2-phenylindole (DAPI) (Molecular 
Probes). Cells were analyzed by using a Leica SPEII 
confocal laser-scanning microscope (Leica Microsystems).
Affinity isolation experiments
Affinity isolation experiments were performed 
as previously described [6]. Briefly, PANC-1 cells were 
plated on dishes (Falcon), and grown to at least 80% 
cells confluence. Biotin-labeled N6L (5 μM, alone or in 
a polyplexed form) was diluted in DMEM supplemented 
with 5 % FCS and incubated with cells for 1 hour at 
37°C and 5% CO2. After washing the cells once in PBS, 
cell extracts were prepared in lysis buffer containing 20 
mM Tris-HCl (pH 7.5, 50 mM NaCl, 5 mM MgCl2), 1 
μl/mL protease inhibitors obtained from Sigma-Aldrich, 
0.5% Triton X100, 1 mM NaF, and 1 mM Na3VO4. The 
complexes formed between biotin-labeled N6L and 
interacting proteins were isolated by purification of the 
extracts, using 100 μL avidin-agarose (Pierce, Thermo 
Fisher Scientific) in PBS containing 1 mM EDTA, 1 mM 
NaF, and 1 mM Na3VO4. After overnight incubation at 
4°C, the samples were washed extensively with the same 
buffer. The purified proteins were subjected to SDS-PAGE 
and Western blot analysis using anti nucleolin antibody 
(rabbit polyclonal, Abcam ab22758).
In vivo experiments
Experiments with human solid tumour xenografts 
in nude mice were carried out as previously described 
[9]. Athymic 4-week-old Nu-NU mice (Janvier Labs, 
Le Genest St Isle), were subcateneously injected with 
either 5 x 106 PANC-1 cells or 1.5 x 106 U87-MG cells. 
When the tumour reached about 40 mm3, the mice were 
separated randomly in several groups, then treated 
with an intraperitoneal injection of either N6L (2 mg/
kg of body weight) or N6L polyplexes (2 mg/kg, ratio 
CS-C/N6L of 1/8 w/w), CS-C (0.26 mg/kg of body 
weight) or PBS as control, three times per week. The 
tumour volume was measured along two major axes 
with calipers. Tumour volumes (mm3) were calculated 
as follows: V = 4/3×π×R1
2×R2, where R1 is radius 1, R2 
is radius 2 and R1<R2. The mouse model of pancreatic 
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ductal adenocarcinoma was obtained by injecting 
orthotopically in a cohort of FVB/n syngenic mice clonal 
tumour lines (0.5 x 103 cells/mouse) isolated from the 
p48-Cre, LSL-KRasG12D; p53flox/wt and the p48-Cre, 
LSL-KRasG12D; Ink4a/Arfflox/wt transgenic PDAC 
models. These cells are mutated for KRas and p53 and 
are null for Ink4a/Arf. When injected into the pancreas 
of immuno-competent FVB/n mice, these lines were able 
to form tumours that recapitulated many feature of the 
spontaneous tumour microenvironment with an average 
latency of 3-4 weeks. One week after cell inoculation, 
PDAC mice were treated 3 times/week for a total of 3 
weeks with an intraperitoneal injection of either N6L (10 
mg/kg) or N6L polyplexes (10 mg/kg, ratio CS-C/N6L of 
1/8 w/w) or vehicle (saline solution) as control. Pancreas 
from mice were dissected and collected. The total tumour 
burden was quantified by measuring with a caliper and 
estimating the volume of individually excised macroscopic 
tumours (>1 mm3) with the formula: V= a x b2 x 0.52, 
where a and b represent the longer and shorter diameter of 
the tumour, respectively. All animal procedures had been 
approved by the Ethical Commission of the University 
of Paris Est-Créteil, the University of Turin, and by the 
French and Italian Ministries of Health in compliance with 
international laws and policies. All in vivo experiments 
were carried out with the approval of the appropriate 
ethical committees, and under conditions established by 
the European Union.
Immunostaining of tumour sections
Frozen tumour sections were processed for 
immunofluorescence as previously described [37]. 
Sections were air-dried, fixed in zinc fixative for 10 
minutes, saturated with BSA 3 %, 1 hour at RT, and 
incubated with either anti-ki67 (DAKO, M0722) or anti-
MECA32 (rat monoclonal, BD Pharmingen 550563, clone 
MECA-32). After washing, sections were incubated with 
anti IgG Alexa Fluor-555 (Life Technology). Nuclei were 
stained with DAPI, and immunofluorescence images 
were captured by confocal microscopy. Acquisitions were 
carried out on multiple tissue sections (5 field per mouse, 
n = 5), and quantification analysis was performed with the 
ImageJ sofware.
Bio-distribution assay
In order to assess the capability of N6L and N6L 
polyplexes to reach and distribute into the malignant 
lesions, a bio-distribution experiment in tumour-bearing 
PDAC mice was performed using green fluorescent 
compounds. N6L-alexa fluor 488 or N6L-alexa fluor 
polyplexes were injected in the tail vein, and mice were 
sacrificed 6 and 12 hours afterward. Pancreas, liver and 
kidney, as control, were excided from each mouse, and 
freshly included in OCT (Tissue Tek). Ten micrometer-
thick sections were cut using a Leica CM1900 cryostat. 
Sections were air-dried, fixed in a zinc fixative (6.05g 
Tris, 0.35g Ca (C2H3O2)2, 2.5g Zn(C2H3O2)2, 2.5g ZnCl2, 
3.8 mL HCl 37%) for 10 minutes, and the nuclei were 
counterstained with diamidino-2-phenylindole (DAPI) 
(Invitrogen). Stainings were analyzed by using a Leica 
SPEII confocal laser-scanning microscope (Leica 
Microsystems).
Statistics analysis
Unless indicated otherwise, bars represent mean +/− 
Standard Error Mean (S.E.M.; n ≥ 3), p values have been 
calculated using a two-tailed or one-tailed unpaired t test 
using GraphPad Prism software. *p < 0.05; **p < 0.01; ***p 
< 0.001.
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Multivalent cationic pseudopeptide polyplexes as a tool for 
cancer therapy
SUPPLEMENTARY MATERIALS
Supplementary Figure 1: Chemical structure of the N6L pseudopeptide, with the KψPR side chains portrayed as blue 
cylinders (counterions are acetate anions); the exact structure of the KψPR subunits is provided on the right side, with 
the attachment point to the backbone indicated by a blue full circle.
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Supplementary Figure 2: Dynamic light scattering (DLS) measurements. Dynamic light scattering (DLS) measurement of 
particle size distribution measured after mixing heparin with N6L in water at 23°C (final concentrations of 14.7 μM and 100 μg/mL for N6L 
and heparin, respectively); representative results from three consecutive measurements of 15 runs each.
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Supplementary Figure 3: Effect of CS-C on the PANC-1 viability. PANC-1 cells were treated with various concentration of 
CS-C ranging from 0.01 to 1000 μg/ml. After 72 hours, cell growth was quantified by AlamarBlue assay according to the recommended 
procedure. Histograms represent the percentage of cell growth relative to the values of untreated cells.
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Supplementary Figure 4: MS determination of N6L presence in the dialysate. A solution of 1 mL of 73 μM N6L or of 1 mL 
of polyplexed N6L, with final concentrations of 73 μM and 10 μg/mL in N6L and CS-C, respectively, were independently dialyzed against 
100 mL of water. 1-mL aliquots were taken at times indicated in the figure, and analysed by mass spectrometry. The peptide with m/z equal 
to 648.637 was identified as N6L.
